FDA Approves Ziextenzo (pegfilgrastim-bmez), a Biosimilar to Neulasta Print this page Holzkirchen, Nov. 5, 2019 – Sandoz, a Novartis division and a global leader in biosimilars, today announced that the US Food and Drug Administration (FDA) approved its biosimilar Ziextenzo (pegfilgrastim-bmez). Sandoz biosimilar pegfilgrastim has been approved and marketed in Europe as Ziextenzo® (pegfilgrastim) since… Read More »
November 5th, 2019 Medgadget Editors Anesthesiology, Critical Care, Emergency Medicine, Medicine, Surgery Med-botics, a firm based in Colorado Springs, won FDA Breakthrough Device status for its Oxalert EPO (Enhanced Pulse Oximeter), a device developed to prevent respiratory arrest from opioid overdoses. Post-op patients and others on heavy opioid therapy can stop breathing, which can lead… Read More »
Haven, the Boston-based healthcare company formed by Amazon, JPMorgan Chase & Co. and Berkshire Hathaway, is testing a new health plan for bank employees, a JPMorgan spokesman has confirmed. The pilot is taking place in two states, confirmed Andrew Gray, managing director corporate communications of JPMorgan Chase. The insurance pilot is being tested in Ohio… Read More »
It’s difficult to stay ahead of data breaches, and healthcare leaders seem to largely agree that it’s only getting more challenging — and that’s bad news for the financial health of the industry, as data breaches are projected to cost healthcare $ 4 billion by the end of the year. 2020 could be even more… Read More »